Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1

Kikuchi, Yoshinori; Shimada, Hideaki; Hatanaka, Yutaka; Kinoshita, Ichiro; Ikarashi, Daiki; Nakatsura, Tetsuya; Kitano, Shigehisa; Naito, Yoichi; Tanaka, Toshimichi; Yamashita, Keishi; Oshima, Yoko; Nanami, Tatsuki

doi:10.1007/s10147-023-02430-x

Cited by 2 publications

(2 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autoantibodies against tumor-associated antigens are used as markers to determine biological properties because they can be measured noninvasively and have a significant advantage in early detection compared with analysis using cancer cells [3]. Based on our experience of analyzing autoantibodies in cancer patients for over 20 years, we believe that glucose metabolism-related enzymes may function as antigens to induce autoantibodies in the blood of cancer patients.…”

Section: Of 13mentioning

confidence: 99%

See 1 more Smart Citation

Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer

Sasajima,

Sumazaki,

Oshima

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group (p = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls (p = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis (p = 0.01), peritoneal dissemination (p < 0.05), and poor overall survival (p < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis (p < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer.

show abstract

Section: Of 13mentioning

confidence: 99%

“…Gastric cancer is the fourth leading cause of cancer-related deaths worldwide [1]. Research into various biomarkers [2,3] and immune-related treatments [4,5] is ongoing to improve early diagnosis and prognosis.…”

Section: Introductionmentioning

confidence: 99%